Medical management of traumatic neuropathies

Oral and Maxillofacial Surgery Clinics of North America

Volumn 13, Issue 2, 2001, Pages 343-363

  Gregg, J M ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRAZOLAM; ANTICONVULSIVE AGENT; BACLOFEN; CANNABINOID DERIVATIVE; CAPSAICIN; CARBAMAZEPINE; CLONIDINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DEXTROPOPOXYPHENE; FLUOXETINE; GABAPENTIN; GLUTAMIC ACID; KETAMINE; KETOBEMIDONE; LAMOTRIGINE; LIDOCAINE; MEXILITINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SODIUM CHANNEL BLOCKING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; XANAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BRAIN STEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; HUMAN; MOLECULAR BIOLOGY; NERVE BLOCK; NERVE CELL PLASTICITY; NERVE INJURY; NERVE STIMULATION; NEUROPATHY; NEUROPHARMACOLOGY; NEUROTRAUMATOLOGY; NONHUMAN; PATIENT COMPLIANCE; RAT; SIDE EFFECT; TRIGEMINUS NEURALGIA;

EID: 0035165398     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (207)

1. Postherpetic neuralgia: Response to topical clonidine
2. Neural blockade for neuropathic pain
3. Recommendations for clinical guidelines for pharmacotherapy of intractable pain of cancerous and non-cancerous etiology
4. Use of animal model to evaluate the origin and protection against deafferentation pain
5. Uninjured C-fiber nociceptors develop spontaneous activity and alpha-adrenergic sensitivity following L6 spinal nerve ligation in the monkey
6. The effect of ketamine on stimulation of primary and secondary hyperalgesic areas induced by capsaicin: A double-blind, placebo-controlled, human experimental study
7. New analgesics for neuropathic pain: The lidocaine patch
8. Prolonged relief of neuralgia after regional anesthetic blocks: A call for further experimental and systematic clinical studies
9. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
10. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: A pilot study
11. Intravenous lidocaine in central pain: A double-blind, placebo-controlled, psychophysical study
12. Local anesthetics as adjuvant analgesics
13. Anticonvulsants (antineuropathics) for neuropathic pain syndromes
14. Gabapentin for the symptomatic treatment of painful neuropathies in patients with diabetes mellitus
15. Clonazepam for the treatment of lancinating phantom pain
16. The safety and efficacy of intrathecal adenosine in a patient with chronic neuropathic pain
17. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
18. Morphine and NMDA receptor antagonism reduce c-fos expression in spinal trigeminal nucleus produced by acute injury to the TMJ region
19. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy
20. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice
21. Recent advances in understanding of vanilloid receptors: A therapeutic target for treatment of pain and inflammation in skin
22. Sympathetic nerve sprouting fails to occur in the trigeminal ganglion after peripheral nerve injury in the rat
23. Spontaneous and mechanically evoked afferent activity originating from myelinated fibers in ferret inferior alveolar nerve neuromas
24. Ketamine injection used orally
25. The utilization and mechanism of action of tricycllic antidepressants in the treatment of chronic facial pain: Review of the literature
26. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage "enriched enrollment" design
27. Is nociceptor activation by alpha-1 adrenoreceptors the culpril in sympathetically maintained pain?
28. Use of opioid analgesics for the treatment of chronic non-malignant pain: A consensus statement and guidelines from the Canadian Pain Society
29. Lamotrigine control of central pain
30. Gabapentin as an adjuvent to opioid analgesia for neuropathic cancer pain
31. Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats
32. The capsaicin receptor: A heat-activated ion channel in the pain pathway
33. The use of oral mexilitine for the treatment of pain after peripheral nerve injury
34. Pain response to preineuromal injection of normal saline, epinephrine, and lidocaine in humans
35. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodyria in the rat
36. Combined systemic administration of the glycine/NMDA receptor antagonist, (+)-HA966 and morphine attenuates pain-related behavior in a rat model of trigeminal neuropathic pain
37. The reflex sympathetic dystrophy response to treatment with systemic corticosteroids
38. The orofacial formalin test in rats: Effects of different formalin concentrations
39. The formalin test: A validation of the weighted scores method of behavioral pain rating
40. Opioid receptors on peripheral sensory axons
41. The effects of lamotrigine and morphine on neuropathic pain in the rat
42. The perceived effects of smoked cannabis on patients with multiple sclerosis
43. A new version of the thalamic disinhibition hypothesis of central pain
44. Topical application of clonidine relieves hyperalgesia in patients with sympathetically mediated pain
45. Successful treatment for phanton pain
46. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain
47. Are opioids effective in relieving neuropathic pain?
48. Do benzodiazepines have a role in chronic pain management?
49. Randomized double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain
50. Isolation and structure of a brain constituant that binds to the cannabinoid receptor
51. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction
52. A cure for wind up: NMDA receptor antagonists as potential analgesics
53. Where and how opioids act
54. NMDA receptor antagonists: Interaction with opioids
55. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord
56. Spinal dorsal horn plasticity following tissue or nerve injury
57. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-D-aspartic receptor blockade
58. Clinical trials of NMDA-receptor antagonists as analgesics
59. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation
60. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post herpetic neuralgia
61. Relief of postherpetic neuralgia with the N-methyl-D-aspartic acid antagonist ketamine: A double-blind cross-over comparison with morphine and placebo
62. The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain
63. The peripheral analgesic effect of morphine in a rat model of nociceptive and inflammatory pain
64. Adenosine increases the cutaneous heat pain threshold in healthy volunteers
65. Phase III placebo controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients
66. Topical clonidine for orofacial pain: A pilot study
67. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia
68. Neurokinetics of lidocaine in the infraorbital nerve of the rat in vivo
69. Peppers and pain: The promise of capsaicin
70. Spinal actions of cyclooxygenase isozyme inhibitors
71. Clinical and experimental aspects of injection injuries of peripheral nerves
72. Enhancement of pentazocine analgesia by clonidine
73. Painful neuropathy: Altered central processing maintained dynamically by peripheral input
74. Transdermal non-steroidal antiinflammatory agents
75. Light and electron microscopic features of human trigeminal neuromas
76. Guidelines for opioid use in non-malignant pain
77. Guidelines for managing chronic non-malignant pain: Opioids and other agents
78. Efficacy and safety of controlled-release vs immediate-release oxycodone: Randomized, double-blind evaluation of patients with chronic back pain
79. Characteristics of ectopic discharges in a rat neuropathic pain model
80. The analgesic effect of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
81. The use of NMDA-receptor antagonists in the treatment of chronic pain
82. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar corsal horn of the rat
83. Splinting and local steroid injection for the treatment of ulnar neuropathy at the elbow: Clinical and electrophysiological evaluation
84. Effect of N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans
85. Subanesthetic concentrations of lidocaine selectively inhibit a nociceptive response in the isolated rat spinal cord
86. The sympathetic nervous system in pain
87. Opioids for chronic cancer and non cancer pain: A survey of state medical board members
88. Trends in medical use and abuse of opioid analgesics
89. Antidepressant medications and the relative risk of suicide attempt and suicide
90. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection
91. How do drugs relieve neurogenic pain?
92. An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist
93. MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients
94. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat
95. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes
96. Desipramine relieves post-herpetic neuralgia
97. Chronic functional consequences of adult infraorbital nerve transection for trigeminal rat subnucleus interpolaris
98. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia
99. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
100. The NMDA-receptor antagonists CPP abolishes neurogenic "windup pain" after intrathecal administration in humans
101. Strain differences in adrenergic sensitivity of neuropathic pain behaviors in an experimental rat model
102. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists
103. Sprouting of A beta fibers into Lamina II of the rat dorsal horn in peripheral neuropathy
104. Neuronal activity in the region of the thalamic principal nucleus (ventralis caudalis in patients with pain following amputations
105. Peripheral and central mechanisms of NGF-induced hyperalgesia
106. Windup leads to characteristics of central sensitization
107. The treatment of periocular and facial pain with topical capsaicin
108. Analgesic drugs for neuropathic and sympathetically maintained pain
109. Tic douloureux and atypical facial pain
110. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition
111. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy
112. Lidocaine test in neuralgia
113. The structure of the cannabinoid receptor and functional expression of the cloned cDNA
114. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial
115. Antidepressants as analgesics
116. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: A double-blind comparison to alfentanil and placebo
117. Association of pain relief with drug side effects in postherpetic neuralgia: A single-dose study of clonidine, codeine, ibuprofen, and placebo
118. 200mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomized, double-blind, placebo controlled trial
119. Peripheral-nerve injury triggers noradrenergic sprouting within dorsal root ganglia
120. A systematic review of antidepressants in neuropathic pain
121. Anticonvulsant drugs for management of pain: A systematic review
122. Successful treatment of reflex sympathetic dystrophy with gabapentin
123. The McGill Pain Questionnaire: Major properties and scoring methods
124. Ineffectiveness of dextromethorpham in cancer pain
125. Does opioid analgesia show a gender preference for females?
126. Coupling of sympathetic and somatosensory neurons following nerve injury: Mechanisms and potential significance for the generation of pain
127. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy
128. Molecular characterization of a peripheral receptor for cannabinoids
129. The clinically available NMDA receptor antagonist memantine is antinociceptive on rat spinal neurones
130. Gabapentin in the management of neuropathic pain
131. The effect of ketamine on phantom pain: Central neuropathic disorder maintained by peripheral input
132. Gabapentin: A new tool in the treatment of neuropathic pain
133. Mechanisms of central pain
134. Pain and allodynia in postherpetic neurallgia: Role of somatic and sympathetic nervous system
135. Comments on topical clonidine for relief of allodynia
136. Antidepressant-induced analgesia in chronic nonmalignant pain: A meta-analysis of 39 placebo-controlled studies
137. Topical medications for orofacial neuropathic pain: A review
138. Intravenous and oral anesthetics in pain management: Reflections on lidocaine and mexilitine
139. Analgesic efficacy of the kappa-receptor agonist, endoline, in dental surgery pain
140. Ethical issues in the management of chronic nonmalignant pain
141. The molecular biology of mu opioid analgesia
142. Causalgia, pathological pain, and adrenergic receptors
143. A new human experimental pain model: The heat/capsaicin sensitization model
144. The effect of systematically administered recombinant nerve growth factor in healthy human subjects
145. Parietal and cingulate processes in central pain: A combined positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) study of an unusual case
146. Chronic opioid therapy in non-malignant pain
147. Opioid therapy for chronic non-malignant pain
148. Addiction rare in patients treated with narcotics
149. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man
150. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial
151. The perception of phantom limbs. The H.O. Hebb Lecture
152. Causes and consequences of sympathetic basket formation in dorsal root ganglia
153. Trigeminal neuralgia: The role of self-sustaining discharge in the trigeminal ganglion
154. Potentiation of delta-9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of mu and kappaopioid receptors
155. Opioid analgesics and antagonists
156. Cannabinoids modulate pain by multiple mechanisms of action
157. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
158. Spontaneous neuronal hyperactivity in the medial and intralaminar thalamic nucleic of patients with deafferentation pain
159. Clinical applications of capsaicinoids
160. The effect of gabapentin on neuropathic pain
161. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia
162. Recent developments in the treatment of neuropathic pain
163. Gabapentin for the treatment of post-herpetic neuralgia: A randomized controlled trial
164. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia
165. Gabapentin adjunctive therapy in neuropathic pain states
166. Adenosine receptor activation and nociception
167. Peripheral morphine analgesia in dental surgery patients
168. The analgesic effect of amitriptyline on facial pain
169. Intrathecal lithium reduces neuropathic pain responses in a rat model of peripheral neuropathy
170. Tramadol relieves pain and allodynia in polyneuropathy: A randomized, double-blind, controlled trial
171. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
172. Intrathecal and systemic R-phenylisopropyl-adenosine reduces scratching behavior in a rat mononeuropathy model
173. The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol
174. Systemic adenosine infusion: A new treatment modality to alleviate neuropathic pain
175. Fibromyalgia: Are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs
176. Complex regional pain syndrome (Type I, RSD; Type II, Causalgia): Controversies
177. Deafferentation pain after posterior rhizotomy, trauma to a limb, and herpes zoster
178. Anticonvulsant drugs and chronic pain
179. Vanilloid receptors: New insights enhance potential as a therapeutic target
180. The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case
181. Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: Lidocaine, carbamazepine, and mexilitine
182. Hyperalgesia due to nerve damage: Role of nerve growth factor
183. Central nervous system abnormalities in complex regional pain syndrome (CRPS): Clinical and quantitative evidence of medullary dysfunction
184. The formalin test: An evaluation of the method
185. Noradrenalin-evoked pain in neuralgia
186. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
187. Pharmacokinetics of EMLA cream 5 percent applications to oral mucosa
188. Behavioral assessment of facial pain in rats: Face grooming patterns after painful and non-painful sensory disturbances in the territory of the rat's infraorbital nerve
189. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve
190. Calcium and sodium channel antagonists for the treatment of pain
191. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal of burn-induced secondary hyperalgesia in man: A double-blind, cross over comparison with morphine and placebo
192. The treatment of neuropathic pain: Antidepressants and opioids
193. Amitriptyline versus placebo in postherpetic neuralgia
194. Opioid pseudoaddiction: An iatrogenic syndrome
195. Immunohistochemical localization of delta opioid receptors in peripheral tissues
196. Effectiveness of alprazolam in the treatment of chronic pain: Results of preliminary study
197. Mechanisms of central pain
198. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity
199. Peripheral nerve injury triggers central sprouting of myelinated afferents
200. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: Implications for treatment of post-injury pain hypersensitivity states
201. Functional changes in dorsal root ganglion cells after chronic nerve constriction
202. The depressive effect of intrathecal clonidine on the spinal flexor reflex is enhanced after sciatic nerve section in rats
203. Lamotrigine (lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo controlled crossover trial
204. Drugs used in the management of trigeminal neuralgia
205. Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia